Shukra Pharmaceuticals Limited

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-05-31 am EDT			5-day change	1st Jan Change
100.8 ^INR	-1.99%		-9.38%	+225.98%

May. 29	Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	CI
Feb. 12	Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director

October 06, 2023 at 09:49 am EDT

Shukra Pharmaceuticals Limited announced that Mr. Jivansingh Gangasingh Negi Independent Director of the company has vide his resignation letter dated October 06, 2023, resigned from the Board of the Company with immediate effect, on account of personal reasons.

Latest news about Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	May. 29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 11	CI
Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director	23-10-06	CI
Shukra Pharmaceuticals Limited Announces Board Changes	23-08-16	CI
Shukra Pharmaceuticals Limited Announces Directorate Resignations	23-08-16	CI
Shukra Pharmaceuticals Limited Announces Executive Changes	23-08-12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Shukra Pharmaceuticals Limited Announces Resignation of Ashvin Trivedi as Non- Executive Director, Effective August 12, 2023	23-08-07	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023	23-05-29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Shukra Pharmaceuticals Limited Announces Board Changes	22-11-12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Shukra Pharmaceuticals Limited Approves Final Dividend for the Financial Year 2021-22	22-10-01	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	22-09-05	CI
Shukra Pharmaceuticals to Raise Up to $2.4 Million from Equity Offering	22-08-25	MT
Shukra Pharmaceuticals Limited Appoints Rai Kavoorguthu Konark as Additional Independent Director	22-08-25	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-06	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-28	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	22-05-28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-12	CI
Shukra Pharmaceuticals Limited Announces Resignation of Nileshkumar Patel as Director	22-02-03	CI

Chart Shukra Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHUKRA PHARMACEUTICALS LIMITED	+225.98%	52.91M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B